Boston Biotech Business Development Conference

Download IconDownload Print IconPrint

Boston Biotech Business Development Conference

Speaking Engagement
The Boston Biotech Business Development Conference is a networking forum for industry professionals offering exclusive access to key decision-makers who influence deal-making and investment in the life sciences. Attendees will gain insights from presentations and panels featuring business development decision-makers from several of the world's leading pharmaceutical and biotechnology companies on the current and future outlook for licensing, M&A and other business development activities in the life sciences sector. In addition to sharing insights on what it takes to get a deal done in biotech, the conference will also offer opportunities to network one-on-one with the industry's top deal makers, including senior executives from biotech and pharma, leaders from Wall Street and venture capitalists.

WilmerHale Partner Hal Leibowitz will moderate a panel titled “M&A Activity in 2013: Who Benefits Most, Pharma or Biotech?” on Tuesday, April 2 from 4–4:30 p.m., and WilmerHale Partner David Redlick will moderate a panel titled “The Deals of Tomorrow: Predictions and Wish Lists” on Wednesday, April 3 from 3–3:30 p.m.

Read More About the Event

Speakers

You May Be Interested In

41st Annual Representing and Managing Tax-Exempt Organizations Conference

April 18–19, 2024
Speaking Engagement

Cybersecurity and Privacy Protection Conference 2024

April 18–19, 2024
Speaking Engagement

Managing Cyber Risks in 2024: Regulatory Compliance, Litigation Risk, Third-Party Cybersecurity Incident Exposure

April 24, 2024
Speaking Engagement
View all Events

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel